BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#296 of 347

John Newman

Canaccord Genuity · Equity Research Analyst
ProvisionalRating since 2017No new ratings since Mar 2025

Analyst rating accuracy & track record

John Newman is an equity research analyst at Canaccord Genuity. Bullish Whales has scored 23 of their stock calls across 10 companies. Their picks beat their sector 30% of the time over the next 12 months, and their price targets were reached 29% of the time within a year.

Win % vs sector
30%
PT Hit % (12mo)
29%
Avg sector-excess
−21.1%
Scored calls
23
Tickers
10
Tier
Provisional

Track record

Bullish Whales has scored 23 of John Newman's stock calls across 10 companies, dating back to 2017. Their rated stocks beat their own sector 30% of the time over the next 12 months. On a typical call, a Newman pick returned −21.1% more than its sector over the following year.

Of the scored calls, 23 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ALLOAllogene Therapeutics Inc
Buy$14.00Mar 2025+27.2%Miss
ATRAAtara Biotherapeutics Inc
Buy$17.00Mar 2025−17.1%Hit
MRKRMarker Therapeutics Inc
Buy$8.00Mar 2025−18.6%Miss
CADLCandel Therapeutics Inc
Buy$25.00Feb 2025−48.9%Miss
CADLCandel Therapeutics Inc
Buy$20.00Feb 2025−60.0%Miss
ATRAAtara Biotherapeutics Inc
Buy$17.00Jan 2025−39.6%Hit
MCRBSeres Therapeutics Inc
Buy$10.00Nov 2024+42.5%Miss
ATRAAtara Biotherapeutics Inc
Buy$21.00Nov 2024−2.7%Miss
DCTHDelcath Systems Inc
Buy$21.00Oct 2024+6.0%Miss
MCRBSeres Therapeutics Inc
Buy$10.00Sep 2024−11.7%Miss
ACETAdicet Bio Inc
Buy$8.00Sep 2024−33.5%Miss
ACETAdicet Bio Inc
Buy$19.00Aug 2024−43.8%Miss
MCRBSeres Therapeutics Inc
Buy$10.00Aug 2024+6.0%Miss
ATRAAtara Biotherapeutics Inc
Buy$13.00Aug 2024+67.8%Hit
MCRBSeres Therapeutics Inc
Buy$10.00Jun 2024−37.7%Miss
ONCYOncolytics Biotech Inc
Buy$5.00Jun 2023−76.1%Miss
ATRAAtara Biotherapeutics Inc
Buy$20.00May 2023−85.5%Miss
MCRBSeres Therapeutics Inc
Buy$15.00Mar 2023−103.3%Miss
MCRBSeres Therapeutics Inc
Buy$11.00Mar 2023−100.8%Miss
ONCYOncolytics Biotech Inc
Buy$5.00Mar 2023−47.4%Miss
MCRBSeres Therapeutics Inc
Buy$29.00Jul 2021−50.1%Miss
RNTXRein Therapeutics Inc
Buy$5.00Apr 2019−83.3%Miss
HCMHUTCHMED DRC
Buy$38.00Oct 2017−6.3%Hit
Go to

John Newman: analyst track record FAQ

Is John Newman a good stock analyst?

Yes, by track record. John Newman ranks number 296 of 347 of the analysts Bullish Whales scores, with a BW Score of 0 out of 100. Past results do not guarantee future ones.

What is John Newman's win rate?

John Newman's win rate is 30%. Across 23 scored calls, their rated stocks beat their sector 30% of the time over the next 12 months. On a typical call they returned −21.1% more than the sector.

What stocks and sectors does John Newman cover?

John Newman covers 10 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are John Newman's price targets accurate?

John Newman's price targets are reached within 12 months 29% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow John Newman's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does John Newman rank among Wall Street analysts?

John Newman ranks number 296 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30